Is Wockhardt (WOCKPHARMA) overvalued or fairly valued?

MarketChacha shows Wockhardt's valuation in context — a price-to-book of about 6.1 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Wockhardt's revenue?

Wockhardt reported revenue of ₹3,988 Cr for FY2017, per official filings.

What is the share price of Wockhardt (WOCKPHARMA)?

Wockhardt last traded at ₹1,861.50 (-3.2% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Wockhardt

WOCKPHARMA · NSE · Pharma · India

₹1,861.50-3.2%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 9:59 AM

Snapshot

TickerWOCKPHARMA

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees2,564

HeadquartersMumbai, India

Market cap₹30,248 Cr

P/B6.1

Volume8.01L

Websitewww.wockhardt.com

Filings tracked0

About Wockhardt

Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters51.0%
Institutions14.5%
Public & other34.5%

48 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

Margin has compressed by about 8.2 points over the period — profitability is trending down.

Net margin trend17.4% → 9.2%

Margin has compressed by about 8.2 points over the period — profitability is trending down.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

₹1,086.7052-wk range₹2,422.30

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Market cap

₹30,248 Cr

Day change

-3.2%

P/B

6.1

Beta

0.93

Revenue (FY2017)

₹3,988 Cr

Revenue CAGR (3y)

-6.2%

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about WOCKPHARMA

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2017	₹3,988 Cr	—	—
FY2016	₹4,461 Cr	—	—
FY2015	₹4,400 Cr	₹405 Cr	9.2%
FY2014	₹4,830 Cr	₹841 Cr	17.4%

Quarterly

Period	Revenue	Net profit	Net margin
2014Q4	₹1,382 Cr	—	—
2014Q3	₹1,029 Cr	—	—
2014Q2	₹991 Cr	₹20 Cr	2.0%
2014Q1	₹1,039 Cr	₹74 Cr	7.2%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.